Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: polyethylene glycol 3350 Clear all
Completed Phase 1Phase 2 Interventional Results available

PillCam® Platform With the PillCam Crohn's Disease Capsule

NCT01631435
View directory record Official record
Conditions
Crohn's Disease
Interventions
Pillcam colon capsule and PillCam™ Prep Procedure, Ileocolonoscopy
Other · Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

NCT04210427
View directory record Official record
Conditions
Cystic Fibrosis Gastrointestinal Disease
Interventions
Polyethylene Glycol 3350, SmartPill Motility System & PillCam Patency Capsule
Drug · Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 1, 2026, 10:38 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

NCT03216356
View directory record Official record
Conditions
PTSD
Interventions
CBT + ImRs, CBT + I.E., D-Cycloserine, Placebo, Study Pill
Behavioral · Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy

NCT04197869
View directory record Official record
Conditions
Constipation, Post-Op Complication
Interventions
Polyethylene Glycol Powder
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bay Shore, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 1, 2026, 10:38 AM EDT
Withdrawn Not applicable Interventional

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

NCT01923376
View directory record Official record
Conditions
Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions
Lactulose, Polyethylene Glycol 3350
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

NCT00171522
View directory record Official record
Conditions
Constipation
Interventions
Tegaserod and Polyethylene Glycol 3350
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
52 participants
Timeline
2005
U.S. locations
14
States / cities
Oro Valley, Arizona • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 1, 2026, 10:38 AM EDT
Not listed Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 1, 2026, 10:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Polyethylene Glycol Safety in Children

NCT05424757
View directory record Official record
Conditions
Polyethylene Glycols, Children, Only
Interventions
PEG 3350
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

NCT07605897
View directory record Official record
Conditions
Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions
Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY)
Other · Drug
Lead sponsor
Joseph Spataro
Federal
Eligibility
18 Years to 69 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy

NCT00953017
View directory record Official record
Conditions
Colonoscopy
Interventions
Miralax (PEG 3350), Amitiza (Lubiprostone), Dulcolax (Bisacodyl), Golytely (polyethylene glycol)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy

NCT01170754
View directory record Official record
Conditions
Colon Cancer
Interventions
PEG-3350 and Gatorade, Golytely 4 liters
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Methylnaltrexone Use for Opioid-induced Postoperative Constipation

NCT01773096
View directory record Official record
Conditions
Constipation
Interventions
Methylnaltrexone, Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 1, 2026, 10:38 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PEG3350 vs Senna After Urogyn Surgery

NCT06825260
View directory record Official record
Conditions
Obstructive Defecation Syndrome, Postoperative Constipation
Interventions
Senna, Polyethylene glycol 3350
Drug
Lead sponsor
St. Joseph's Health, New York
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT02765256
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 1, 2026, 10:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

NCT02938520
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

NCT05896748
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Not applicable Interventional

MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery

NCT01691742
View directory record Official record
Conditions
Post Procedural Constipation
Interventions
MiraLax, Placebo, Rescue Laxative
Drug
Lead sponsor
Duke University
Other
Eligibility
19 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy

NCT03247595
View directory record Official record
Conditions
Colonoscopy
Interventions
Magnesium Citrate Capsules, Polyethylene Glycol 3350, Dulcolax Tablets
Dietary Supplement · Other
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 1, 2026, 10:38 AM EDT
Terminated Phase 4 Interventional Results available

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

NCT02977286
View directory record Official record
Conditions
Constipation
Interventions
Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace], Senna 217 Mg Oral Tablet, Polyethylene Glycols, Bisacodyl 10 mg Suppository, Magnesium Citrate Oral Liquid Product, Methylnaltrexone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Operative Constipation Following Total Knee Arthroplasty

NCT04380090
View directory record Official record
Conditions
Constipation
Interventions
Propylene Glycol, Docusate Sodium
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 90 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 1, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT03476317
View directory record Official record
Conditions
Crohn Disease
Interventions
Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 1, 2026, 10:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 1, 2026, 10:38 AM EDT